Scandion Oncology – Annual Report 2020

Scandion Oncology’s Annual Report 2020 has now been published and is available on the company’s website ( (

Bo Rode Hansen, President & CEO, Scandion Oncology A/S comments:

“In 2020, we met major catalysts with initiation of clinical trials, securing financing, preparing for list change to Nasdaq and internationalization. We saw the first signs of activity with SCO-101 and FOLFIRI in patients. This enabled the company to secure a strong financial position and start building the organization for the future. 

In 2021, we are expecting the first conclusive data to read out from our CORIST study in Q2. We will use the results from the CORIST study together with a new international positioning analysis of the broader commercial platform potential for Scandion Oncology to focus our clinical strategies going ahead.

We will continue to focus on value for patients and shareholders on our journey towards building the Cancer Drug Resistance Company.”

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, President & CEO

Phone: +45 3810 2017



The information was provided by the contact person above for publication on April 29, 2021 CET at 8:30.

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at or +46 (0) 40 200 250.